Trump is a wonder.

Trump strikes Pfizer deal for 85% drug price cuts.

President Donald Trump announced a voluntary agreement with Pfizer in the White House Oval Office, requiring the company to sell medications to Medicaid at the lowest international prices starting in 2026, potentially saving hundreds of millions annually on treatments for cancer, arthritis, and other conditions. The deal includes up to 85% discounts on select drugs and the launch of TrumpRx, an online platform set for early 2026 that redirects users to manufacturers for direct cash purchases with 50-85% savings, bypassing insurers. In exchange, Pfizer committed $70 billion to U.S. manufacturing and research investments, focusing on cancer therapies, obesity drugs, and vaccines, while receiving a three-year tariff exemption; the announcement drew praise for affordability but criticism from vaccine skeptics over the partnership.

In a move that surprises nobody, the Trump administration has named a program to lower drug prices for Americans TrumpRX. The program itself is very ambitious, promising to lower prices by an average of 80-85% on many common drugs.

NBC News: President Donald Trump announced Tuesday that his administration has reached a deal with Pfizer for it to voluntarily sell its drugs at lower prices to Medicaid patients. As part of the deal, Trump said, Pfizer will sell some of its drugs on a new “direct to consumer” website called “TrumpRx.” Trump said the website would be operated by the federal government, but offered few details about how the program would work. The deal Pfizer cut with the White House will give the company a three-year grace period on Trump’s planned tariffs on pharmaceuticals made abroad, which are expected to take effect Wednesday. The agreement on lower prices will cover “a large majority” of Pfizer’s primary care medicines, along with speciality brand-name drugs, which will be offered at discounts averaging 50% and reaching as high as 85%, a spokesperson for the company said. (NBC News)

For years, countries with socialized healthcare systems have relied on American medical innovation and drug manufacturing because their healthcare systems do not have the funds to support such research and development. As the president said, “The United States is done subsidizing the healthcare of the rest of the world.” (Townhall)

Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients

September 30, 2025

ADVANCING MOST-FAVORED-NATION PRICING: Today, President Donald J. Trump announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price).

• The agreement will provide every State Medicaid program in the country access to MFN drug prices on Pfizer products, resulting in many millions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
• The agreement ensures foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Pfizer brings to market.
• The agreement requires Pfizer to repatriate increased foreign revenue on existing products that Pfizer realizes as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
• The agreement requires Pfizer to offer medicines at a deep discount off the list price when selling directly to American patients.

DELIVERING REDUCED COSTS: Today’s actions will result in tangible cost savings to American patients and the healthcare system as a whole. Taken together, more than 100 million patients are impacted by the diseases Pfizer’s medicines treat, and many of those will benefit from the President’s successful negotiation of lower prices for Americans. Examples include:

• Eucrisa, a topical ointment for atopic dermatitis, will be made available at an 80% discount to patients purchasing directly.
• Xeljanz, a widely used oral medication for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, will be available at a 40% discount to patients purchasing directly.
•  Zavzpret, a commonly utilized treatment for migraines, will be sold directly to patients at a 50% discount.

ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION:  President Trump is taking decisive action to rebalance a system that allows pharmaceutical manufacturers to offer low prices to other wealthy nations while charging Americans significantly higher prices.

• According to recent data, the prices Americans pay for brand-name drugs are more than three times the price other Organization for Economic Cooperation and Development nations pay, even after accounting for discounts manufacturers provide in the U.S.
• The United States has less than five percent of the world’s population, yet roughly 75% of global pharmaceutical profits come from American taxpayers.
• Drug manufacturers benefit from generous research subsidies and enormous healthcare spending by the U.S. Government. Instead of passing that benefit through to American consumers, drug manufacturers then discount their products abroad to gain access to foreign markets and subsidize those discounts through high prices charged in America. Americans are subsidizing drug-manufacturer profits and foreign health systems, both in development and once the drugs are sold.

DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients that the political establishment did not believe were possible.

• On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
• On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations

President Trump has been relentless in his effort to address the unfair and outrageous prices Americans pay for prescription drugs:

President Trump: “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”

AUTHOR

Pamela Geller

POST ON X:

EDITORS NOTE: This Geller Report is republished with permission. ©All rights reserved.